Source: Annual Congress 2006 - Evaluation of drugs for lung disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. UshaRani, Shivprakash, M. Naidu, M. Rao, M. Verma (Panjagutta; Hyderabad, Ahmedabad, India). A randomized, double blind, cross-over study to investigate the pharmacodynamic equivalence of salbutamol administered via a new HFA134 inhaler versus Evohaler in mild stable asthmatics. Eur Respir J 2006; 28: Suppl. 50, 1254

Member's Comments

No comment yet.

Related content which might interest you: A multicentre, double-blind, double-dummy, randomized, parallel group study to assess efficacy and safety of beclomethasone dipropionate and ease of handling of a breath operated aerosol inhaler in adults with reversible airways obstruction Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008 A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment Year: 2009 A multi-centre, randomised, cross-over study to investigate therapy adherence with and preference for inhaled maintenance therapy via separate Diskus versus a combination product in one Diskus Source: Eur Respir J 2002; 20: Suppl. 38, 448s Year: 2002 A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Paracetamol increases airway resistance in stable asthmatics: A double blind, randomized, placebo controlled study Source: Annual Congress 2010 - New or old physiological parameters in chronic airway disorders? Year: 2010 A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 Randomized double blind comparison of ciclesonide-formoterol combination inhaler and ciclesonide alone in persistent asthma Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011 A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics. Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Comparison of efficacy and safety of two HFA formulations of fluticasone propionate; a double-blind, randomised, multicentric, parallel group study in patients with persistent moderate asthma Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 A randomized placebo controlled trial of AZD8999 (LAS190792) a novel dual acting bronchodilator in asthmatics Source: International Congress 2017 – Novel studies on bronchodilators and cough Year: 2017 Open, randomized, two-way crossover, pilot study to assess the effect of salbutamol in comparison with ipratropium bromide on central and peripheral airway dimensions in COPD patients Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009 Treatment of asthmatic patients with beclomethason dipropionate (BDP) or budesonide(B)-comparative, randomized, double blind clinical study Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003 A double-blind, single dose, four period, crossover study to demonstrate the equivalence between the two HFA formulations of formoterol fumarate; using serial spirometry measurements for 12 hrs Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Pharmacokinetic interaction of glycopyrronium bromide pMDI and formoterol pMDI: A randomized, open-label, single-dose, 4-way cross-over study Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 A single-dose double-blind study comparing efficacy of two dry powder inhalers containing budesonide and formoterol in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016 A randomized, crossover study to examine the pharmacodynamics and safety of a new antimuscarinic (TD-4208) in COPD Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012 A single blinded randomised trial to compare the efficacy and safety of once daily budesonide (400μg) administered by turbuhaler with beclomethasone dipropionate (400μg) given twice daily through a metered-dose inhaler in patients with mild to Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005 Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021